TCT-629 Troponin rise predicts thirty days outcome in coronary artery disease patients undergoing transfemoral aortic valve replacement for severe aortic stenosis

Abstract

Coronary artery disease is present in about two third of patients undergoing transfemoral aortic valve replacement (TAVR) for symptomatic severe aortic stenosis. Risk assessment for transcatheter aortic valve replacement (TAVR) patients is challenging, and surgical scores do not optimally correlate